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Mild intracellular acidification 
by dexamethasone attenuates 
mitochondrial dysfunction in a 
human inflammatory proximal 
tubule epithelial cell model
T. J. J. Schirris  1,2, J. Jansen 1,3,4,5, M. Mihajlovic  1,5, L. P. van den Heuvel 4,6,  
R. Masereeuw  5 & F. G. M. Russel 1,2
Septic acute kidney injury (AKI) associates with poor survival rates and often requires renal replacement 
therapy. Glucocorticoids may pose renal protective effects in sepsis via stimulation of mitochondrial 
function. Therefore, we studied the mitochondrial effects of dexamethasone in an experimental 
inflammatory proximal tubule epithelial cell model. Treatment of human proximal tubule epithelial cells 
with lipopolysaccharide (LPS) closely resembles pathophysiological processes during endotoxaemia, 
and led to increased cytokine excretion rates and cellular reactive oxygen species levels, combined with 
a reduced mitochondrial membrane potential and respiratory capacity. These effects were attenuated 
by dexamethasone. Dexamethasone specifically increased the expression and activity of mitochondrial 
complex V (CV), which could not be explained by an increase in mitochondrial mass. Finally, we 
demonstrated that dexamethasone acidified the intracellular milieu and consequently reversed LPS-
induced alkalisation, leading to restoration of the mitochondrial function. This acidification also provides 
an explanation for the increase in CV expression, which is expected to compensate for the inhibitory effect 
of the acidified environment on this complex. Besides the mechanistic insights into the beneficial effects 
of dexamethasone during renal cellular inflammation, our work also supports a key role for mitochondria 
in this process and, hence, provides novel therapeutic avenues for the treatment of AKI.
The prevalence of acute kidney injury (AKI) in critically ill patients has rapidly increased over the past two dec-
ades up to 30 to 40% of patients admitted to the intensive care unit1, 2. Overall, AKI is associated with 20% of all 
hospitalised adults worldwide, which results in a high burden on healthcare3. Though depending on AKI severity 
and cause (i.e. prerenal, intrinsic or postrenal), the mortality rate is over 50%, and even less severe manifestations 
are associated with short- and long-term adverse effects, including chronic kidney disease4. The pathogenesis 
of AKI is highly complex and often multi-causal, but the septic form provoked by endotoxins originating from 
gram-negative bacteria is the most common cause of disease onset5.
Currently, no pharmacological therapeutic interventions are approved to prevent or treat AKI. Therefore, 
treatment is limited to mitigating secondary hemodynamic and toxic renal insults and provision of support-
ive measures such as diuretics and renal replacement therapy, predominantly hemodialysis1. A variety of renal 
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protective mechanisms have been explored in vitro for their therapeutic potency in AKI (e.g. antioxidant, 
anti-inflammatory, or anti-apoptotic effects, or the activation of autophagy)6. Still, most of these strategies have 
not yet reached clinical studies, and none are applied in a clinical setting7. Promising clinical effects have recently 
been observed with alkaline phosphatase (AP) in two phase-II trials that demonstrated improved kidney func-
tion in critically ill patients with sepsis-associated AKI8. Mechanistic studies further showed that AP dephos-
phorylates extracellular ATP and ADP being released after lipopolysaccharide (LPS) exposure, which might be 
key in the renal protective effect8. However, further clinical validation should demonstrate the true efficacy and 
efficiency of AP prior to clinical implementation. Another potential replacement therapy includes a bioartificial 
kidney containing renal proximal tubule epithelial cells to correct uraemia. Studies in animal models and patients 
with AKI demonstrated immunomodulatory effects, though controlled randomised multi-centre human studies 
have not yet shown conclusive beneficial evidence9–11.
Recently, treatment of cardiac surgery patients with the glucocorticoid dexamethasone has been proposed 
as a new strategy against AKI12, 13. Dexamethasone-induced attenuation of septic AKI was also demonstrated 
in several in vitro and in vivo models, including diminished cytokine levels, improved glomerular filtration rate, 
suppressed pro-apoptotic proteins and reduced mitochondrial injury, inhibited inducible nitric oxide (NO) syn-
thase (iNOS) activity, and improved fluid balance14–18. In addition, stimulation of multi drug resistance protein-2 
(MRP2) was observed, resulting in enhanced urinary excretion of endo- and xenobiotics19.
Still, the exact molecular mechanism underlying these beneficial effects remains unknown. Increasing evi-
dence points towards the role of mitochondrial dysfunction in the pathophysiology of AKI3, 16, 20, which is in 
agreement with mitochondrial dependence of the proximal as well as the distal nephron segments, as illustrated 
by the high density of these organelles21. Mitochondrial dysfunction was characterised by a decreased cytochrome 
c oxidase (COX; mitochondrial complex IV) expression, most likely under the regulation of increased expression 
of Bcl-2 pro-apoptotic proteins16, and elevated reactive oxygen species (ROS). COX and Bcl-2 protein expression 
were partially restored upon dexamethasone treatment, suggesting a potential mitochondrial mechanism16. In 
addition, peroxisome proliferator-activated receptor gamma (PPARγ) coactivator - 1α (PGC-1α), a known key 
regulator of mitochondrial biogenesis and predominantly expressed in proximal tubules, was suppressed20, 22. 
Upon recovery, PGC-1α was restored, emphasising the pivotal role of mitochondria to treat AKI. However, fur-
ther elucidation of the exact mechanism by which dexamethasone influences mitochondrial homeostasis path-
ways during AKI is required.
To this end, we used human conditionally immortalised proximal tubule epithelial cells (ciPTEC, ref. 23). We 
previously characterised this model and demonstrated a broad range of PTEC-specific transport and metabolic 
functions23. Cells were challenged with LPS to mimic septic AKI and were co-incubated with dexamethasone, 
which improved mitochondrial respiration, mitochondrial respiratory complex activity, membrane potential, and 
attenuated ROS production. These effects of dexamethasone were not mediated via PGC-1α-induced mitochon-
drial biogenesis, but likely associated with a restoration of cellular pH.
Results
Dexamethasone attenuates LPS-induced endotoxemia associated mitochondrial dysfunc-
tion. Production of interleukin (IL)-6 and IL-8 in renal cells was clearly stimulated upon twenty-four-hour 
LPS treatment (42 ± 7 ng·ml−1, p = 0.0016 vs. 37 ± 9 ng·ml−1, p < 0.025, respectively) (Fig. 1a–c), thereby mim-
icking the inflammatory response observed in vivo. This is in agreement with our recent studies on sepsis-in-
duced endotoxemia using ciPTEC8. Upon co-treatment with dexamethasone, the IL-6 production was not 
altered (Fig. 1b), however, IL-8 production was no longer significantly increased compared to vehicle-treated 
cells (Fig. 1c).
Next, we further investigated the cellular responses to LPS by evaluating ROS generation. Exposure of ciPTEC 
to LPS for 24 hours led to increased ROS levels (123 ± 6%, p < 0.001), using a general ROS indicator (Fig. 2a). 
However, increased ROS production was not reflected in elevated mitochondrial superoxide anions levels 
(Fig. 2b). This can be explained by the rapid degradation of superoxide anions into hydrogen peroxide by man-
ganese superoxide dismutase MnSOD or Cu/ZnSOD, and subsequent detoxification, either by the peroxidoxin/
thioredoxin system, catalase, or via the reduction of glutathione (GSH) by glutathione peroxidase (Fig. 2c)24, 25. 
After 24-hour incubation, dexamethasone dose-dependently decreased ROS levels (Supplementary Fig. 1a), but 
high concentrations altered the cellular morphology indicative for cytotoxic effects (Supplementary Fig. 1b–d). 
To avoid such toxic effects we used a low (10 μM) concentration, and to even further minimise the chance on 
adverse effects we combined it with a brief four-hour co-treatment of the cells. This was already sufficient to 
reverse the LPS-induced ROS generation (Fig. 2a), and respiratory inhibition by increasing oxidative phospho-
rylation (OXPHOS) CI- (25 ± 9%, p < 0.031) and mitochondrial complex II (CII)-driven respiration (38 ± 11%, 
p < 0.0046) compared to LPS-treated cells (Fig. 3a–c). Of note, CIV-driven respiration was not reduced after LPS 
treatment, which could be explained by the auto-oxidative potential of the substrates used (i.e. ascorbate and 
N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD)) leading to a decreased sensitivity (Fig. 3c). Importantly, 
respiratory inhibition by LPS was only apparent upon maximal stimulation of the respiratory chain in permea-
bilised cells, as observed for the respiration driven by CI (32 ± 13%, p = 0.00041), CII (27 ± 13%, p = 0.000061), 
and glycerol-3-phosphate dehydrogenase (G3PDH; 34 ± 16%, p = 0.0087) respiration, but not under basal condi-
tions (Fig. 3b,c). Such a specific pattern points to a lower mitochondrial respiratory reserve capacity because of a 
reduced mitochondrial membrane potential or a decreased substrate availability. The ATP produced per oxygen 
atom reduced by the OXPHOS system (i.e. phosphate: oxygen (P:O) ratio), provides an indication for the mito-
chondrial coupling of both processes. The tendency of LPS to increase the P:O is in line with a decreased coupling 
(Fig. 3d), which was confirmed by the mitochondrial membrane potential (Fig. 3e). Dexamethasone co-exposure 
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counterbalanced the LPS-induced depolarisation, corroborating the other beneficial effects on mitochondrial 
function, and even showed hyperpolarisation (Fig. 3e; 124 ± 5%, p = 0.00012).
Dexamethasone increases OXPHOS complex V activity and its expression. Respiratory inhi-
bition combined with a decreased mitochondrial membrane potential after LPS exposure could potentially be 
explained by a direct inhibition of one of the OXPHOS complexes. We could, however, not detect inhibition of 
LPS on the enzyme activity of the individual CI to CV activities (Fig. 4). Surprisingly, CV enzyme activity was 
enhanced upon dexamethasone treatment (123 ± 10%, p = 0.046), and, but not significantly, when cells were 
co-exposed to LPS and dexamethasone (Fig. 4). The increased CV activity could provide an explanation for the 
increased mitochondrial membrane potential, when the complex runs into reverse mode (i.e. pumps electrons 
from the mitochondrial matrix to the intermembrane space at the expense of ATP). Besides an increase in the 
intrinsic enzyme activity, induction could also be due to an enhanced CV expression. However, citrate synthase 
activity, a marker of mitochondrial mass, did not change upon dexamethasone or LPS exposure (Fig. 5a). To 
exclude a role of mitochondrial biogenesis, the expression of the master regulator of this process, PGC-1α, was 
investigated (Fig. 5b)26. Resveratrol, a positive control, induced nuclear PGC-1α expression, but no significant 
changes were found after four hours dexamethasone treatment (Fig. 5c). Using immunocytochemistry, we could 
confirm increased CV expression per mitochondrial pixel (Fig. 6; 140 ± 6%, p = 0.0001) that was reduced by 
rapamycin, a mammalian target of rapamycin (mTOR)-dependent mitophagy inducer. To investigate whether 
the increased expression was specific for CV, CIV expression was determined (Fig. 7), which was up-regulated by 
resveratrol but not by dexamethasone (Fig. 7c).
Dexamethasone reverses LPS-induced cellular alkalisation. The increased CV expression could 
potentially be explained as a compensatory mechanism of the reduced intracellular pH upon dexamethasone 
treatment, as an acidified milieu is known to inhibit activity of the complex27, 28. Indeed, the cellular pH measured 
as 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxy methyl ester (BCECF) ratio increased after 
LPS exposure, indicative of alkalisation (Fig. 8a,b; 114 ± 2%, p = 0.00000089). This pH increase is in line with 
Figure 1. Dexamethasone co-treatment reduced IL-6 and IL-8 cytokine production in LPS-induced 
endotoxsemia. (a) To induce endotoxaemia, ciPTEC were exposed to 10 μg/mL lipopolysacharide (LPS) 
for 20 hours. Subsequently, the cells were co-treated with dexamethasone (10 μM, Dex) for 4 hours, and (b) 
interleukin (IL)-6 and (c) IL-8 cytokine excretion into the culture medium was measured by ELISA. Statistical 
analysis: one-way ANOVA with Tukey’s post-hoc analysis compared to vehicle control (Ct): *p < 0.05, 
**p < 0.01, ***p < 0.001. Mean ± SEM, n = 5 independent experiments.
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the decreased mitochondrial membrane potential (Fig. 3e), which depends on the ΔpH between the matrix 
(~7.8) and intermembrane space (~7.0). The mitochondrial outer membrane is permeable for protons, thus the 
pH of the intermembrane space will be equal to the cytosolic pH. A raise in intracellular pH will, therefore, cause 
dissipation of the ΔpH and consequently the mitochondrial membrane potential. When co-exposed to dexa-
methasone, a small but significant cellular acidification was found (Fig. 8b; 87 ± 2%, p = 0.0055). As mentioned, 
this will result in a minor inhibition of CV, which contributes to the restoration of the LPS-induced decrease in 
mitochondrial function.
Discussion
AKI associates with high mortality rates of approximately one out of three intensive care patients29, as effi-
cient treatment modalities are absent. Due to the pivotal role of mitochondria in AKI outcome, restoration of 
their function is expected to have great therapeutic potential3. We confirmed their involvement in experimen-
tal inflammatory conditions using human ciPTEC. We also demonstrated that dexamethasone attenuates the 
LPS-induced inflammatory response, illustrated by a reduced cytokine excretion. Simultaneously, dexamethasone 
induced an intracellular acidification, which coincided with its beneficial effects on LPS-induced mitochondrial 
dysfunction, including decreased mitochondrial respiration and membrane potential and increased ROS gen-
eration. Previously, AKI-associated mitochondrial mechanisms were predominantly attributed to a decreased 
metabolic capacity, such as an increased ROS generation, decreased mitochondrial biogenesis and mitochondrial 
permeability pore opening, eventually leading to apoptosis3, 20.
Although dexamethasone-induced changes in intracellular pH have not been associated with the beneficial 
effects in AKI, intracellular acidification has been observed in PTEC. This is explained by a stimulating effect 
on the basolateral sodium-bicarbonate (Na+:HCO3−) co-transporter (NBC1) and the sodium-proton (Na+, H+) 
exchanger (NHE3) at the luminal side30, 31, which together with Na+, K+-ATPase activity are responsible for the 
Figure 2. LPS-induced endotoxaemia is characterised by ROS generation and is attenuated by dexamethasone 
treatment. After dexamethasone and/or LPS exposure (Fig. 1a) the generation of reactive oxygen species 
(ROS) is examined using (a) 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester 
(CM-DCF) or (b) hydroethidium for the detection of general cellular ROS species or superoxide anions 
(O2−•), respectively. Values were normalised to control (Ct): CM-DCF (766 ± 64 arbitrary intensity units), 
hydroethidium (343 ± 64 arbitrary intensity units). (c) Cellular fate of superoxide anions into reactive nitrogen 
species (NO−•, ONOO−•), hydroxyl radicals (OH−•) and hydrogen peroxide (H2O2), which is catalysed by 
different enzymes (grey spheres), including manganese or copper/zinc superoxide dismutase (MnSOD, Cu/
ZnSOD), catalase (CAT), glutathione peroxidase (GPx), and the peroxidoxin/thioredoxin (Prx/Trx) system 
catalysed by thioredoxin reductase (TrxR). Statistic analysis: one-way ANOVA with Tukey’s post-hoc analysis: 
*p < 0.05, ***p < 0.001. Mean ± SEM, n = 3 independent experiments.
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renal bicarbonate reabsorption under physiological conditions32. Although the acid-base balance determining the 
intracellular pH is regulated by many mechanisms either providing buffering power of acid or base transport, one 
possible mechanism by which dexamethasone could induce the observed slight intracellular acidification is by the 
previously illustrated increase in the transporter activity of NBC1 and NHE3 and increased NBC1 expression30. 
Combined with a stoichiometry of 1:3 for the Na+:HCO3− efflux, the net effect of dexamethasone causes a drop in 
the intracellular HCO3− concentration and consequently in the pH30, 31, 33. However, NHE3 expression has been 
demonstrated to increase upon LPS exposure in monocytes34 and leads to an extracellular acidification in prox-
imal tubule cells35. This is associated with inflammatory conditions and decreased cytokine production rates in 
Figure 3. LPS-induced endotoxaemia leads to severe mitochondrial dysfunction that is restored by 
dexamethasone treatment. (a) Cells were treated with LPS and/or dexamethasone as described in detail in 
Fig. 1a. (b) Next, cells were harvested and transferred to the chambers of the respirometer to determine routine 
oxygen consumption. (c) After permeabilisation of the plasma membrane, OXPHOS complex I (CI)-, CII-, 
glycerol-3-phosphate dehydrogenase (G3PDH)-, and CIV-driven oxygen consumption rates were measured. 
(d) Before measurement of these complex-specific respiratory rates the mitochondrial coupling (e.g. coupling 
between the respiratory chain, ATP production and mitochondrial membrane potential) was determined using 
the phosphorus:oxygen (P:O) ratio. This ratio was calculated dividing the amount of ADP used by the amount 
of oxygen consumed to use all the ADP (220 nM). (e) Alternatively, mitochondrial coupling was determined by 
directly measuring the mitochondrial membrane potential using the cationic dye tetramethylrhodamine methyl 
ester (TMRM). Values were normalised to control (Ct): 158 ± 22 arbitrary intensity units. Statistic analysis: 
one-way ANOVA with Tukey’s post-hoc analysis: *p < 0.05, **p < 0.01, ***p < 0.001. Mean ± SEM, n = 3 
independent experiments.
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epithelial cells36, illustrating the complex interplay of the different pathways affected by LPS and dexamethasone, 
and the need to further investigate the exact molecular mechanisms relevant to the observed pH effects.
The drop in intracellular pH after co-treatment with dexamethasone does provide an explanation for the 
observed up-regulation of mitochondrial CV expression, as the slightly acidified environment is known to inhibit 
CV27, 28, and can also be observed in iron- and ethanol-induced mitochondrial dysfunction. Consequently, this 
can be considered as a more general response to mitochondrial damage37, 38. In addition, our results provide an 
explanation for the previously observed increased expression of CV and the adenine nucleotide translocator39, as 
both are inhibited by a low intracellular pH27, 28. The latter also emphasises the important role of the cellular pH 
in the observed mitochondrial responses after LPS and dexamethasone treatment.
In addition, dexamethasone is expected to have other beneficial effects on the progression of AKI. 
Dexamethasone has been demonstrated to increase the renal microvascular oxygenation, which will improve 
the respiratory capacity while increasing the oxygen availability18. Although equivocal results were obtained, 
dexamethasone is also expected to decrease the iNOS-dependent NO formation, which will lead to attenuate its 
vasodilatory action and formation of nitrogen radicals17, 18. All studies did, however, demonstrate a decreased 
iNOS expression, which may indicate an additional source of oxidative stress. Mitochondria could account for 
this additional source as they are a major ROS generation site containing 11 ROS-producing enzymes (mainly 
by complex I, II, and III, pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase)24. Although our results 
indicate a central role of mitochondria in the beneficial effects of dexamethasone, which is supportive for its 
ROS-lowering activity, we cannot exclude other dexamethasone effects. For example, dexamethasone appeared 
to be an inhibitor of NADPH oxidase (NOX)-2-dependent ROS generation as well40.
Until now almost all in vivo and patient studies showed beneficial effects of dexamethasone in a prophylactic 
setting12, 15, 17, 20. This warrants further investigation of the potential beneficial effects of dexamethasone treatment 
at the manifestation of AKI in animal models and patients. However, its narrow therapeutic window, in general, 
limits dexamethasone intervention. This is probably also the main reason for the equivocal results obtained in 
clinical trials, whereas our findings with dexamethasone on cellular morphology and ROS levels may indicate 
beneficial effects of low-dose treatments opposed to no or detrimental effects of high-dose regimens12, 13, 17, 18. 
Future research should provide better insight into the balance between efficacy and safety of dexamethasone 
therapy. Alternatively, novel pharmaceutical interventions could be investigated, which also target the cellular pH 
without impacting the adverse mechanisms activated upon high-dose dexamethasone treatment.
In conclusion, we provide mechanistic insights into the observed beneficial effects of dexamethasone in AKI 
and provide evidence for a key role of mitochondria in the disease. Furthermore, we demonstrated the impor-
tance of this mechanism for the development of inflammatory conditions, in addition to mitochondria-mediated 
apoptosis in AKI3, 39. Modulating the pH of proximal tubule might be a novel therapeutic approach for treatment 
of patients suffering from septic AKI.
Materials and Methods
Chemicals and cell culture materials. Chemicals were purchased from Sigma-Aldrich unless stated oth-
erwise. Cell culture plates were purchased from Greiner Bio-One.
Cell culture and experimental design. Human conditionally immortalised PTEC isolated from kidney 
tissue (ciPTEC-T123) were cultured in phenol-red free DMEM-HAM’s F12 medium (Lonza) containing 10% 
(v/v) FCS (Greiner Bio-One), insulin (5 µg/ml), transferrin (5 µg/ml), selenium (5 µg/ml), hydrocortisone (36 ng/
ml), EGF (10 ng/ml) and tri-iodothyronine (40 pg/ml) (complete PTEC medium23). In all experiments, cells were 
seeded using a density of 25,000 cells/cm2 on uncoated surfaces, unless stated otherwise. Cells were maintained 
Figure 4. Dexamethasone leads to an increased enzyme activity of OXPHOS complex V without affecting the 
activity of complex I-IV. After LPS and dexamethasone (Fig. 1a) exposure cells were harvested and complex 
I-V (CI-CV) enzyme activity was measured spectrophotometrically. Values were corrected for cellular protein 
and normalised to control (Ct): CI (160 ± 9 U·mg protein−1), CII (220 ± 7 U·mg protein−1), CIII (202 ± 6 U·mg 
protein−1), CIV (183 ± 10 U·mg protein−1), CV (282 ± 87 U·mg protein−1). Statistic analysis: two-way ANOVA 
with Bonferroni’s post-hoc analysis: *p < 0.05, ***p < 0.001. Mean ± SEM, n = 3 independent experiments.
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at 33 °C, 5% (v/v) CO2 for 24 hours, to proliferate and subsequently transferred to 37 °C, 5% (v/v) CO2 for 7 days 
to mature. On day 6, cells were exposed to control medium (complete PTEC medium) or medium supplemented 
with LPS (10 µg/ml, ref. 41) for 24 hours at 37 °C, 5% (v/v) CO2 to induce endotoxaemia (see also Fig. 2a). After 
20-hour incubation, control or LPS-treated cells were co-incubated in the presence or absence of dexamethasone 
(10 µM).
Enzyme-linked Immuno Sorbent Assay. The cytokine production of interleukin-6 (IL-6; #DY206, R&D 
systems) and -8 (IL-8; #DY208, R&D systems) in ciPTEC under control or inflammatory conditions in the pres-
ence or absence of dexamethasone was quantified using Enzyme-Linked Immuno Sorbent Assays (ELISAs) as 
previously described by Schophuizen et al.42. The optical density of each well was measured using an iMark 
Microplate reader (BioRad) set to 460 nm and were background corrected using readings obtained at 540 nm.
Figure 5. Mitochondrial mass and PGC-1α expression are not affected by dexamethasone. (a) Following LPS 
and/or dexamethasone treatment (Fig. 1a), cells were harvested and citrate synthase activity was measured 
spectrophotometrically as a measure of mitochondrial mass. Values were corrected for cellular protein and 
normalised to control (Ct): 362 ± 28 U·mg protein−1. Statistic analysis: one-way ANOVA with Tukey’s post-
hoc analysis: no statistical differences were observed. Mean ± SEM, n = 3 independent experiments. (b) The 
expression of peroxisome proliferator-activated receptor gamma (PPARγ) coactivator - 1α (PGC-1α), a master 
regulator of mitochondrial biogenesis, was measured using immunocytochemistry after 4 hours dexamethasone 
treatment (10 µM, Dex). In addition, cells were incubated for 48 hours with rapamycin (500 nM) or resveratrol 
(10 µM) as known negative and positive regulators of PGC-1α and mitochondrial mass (c) The nuclear PGC-1α 
expression was quantified using a nuclear mask based on 4′,6-diamidino-2-phenylindole (DAPI) staining. 
Values were normalised to control (Ct): 15,900 ± 370 arbitrary intensity units. Statistic analysis: one-way 
ANOVA with Dunnett’s post-hoc analysis: ***p < 0.001. Mean ± SEM, n ≥ 253 individual cells analysed in 
n = 3 independent experiments.
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Figure 6. Dexamethasone increases OXPHOS complex V expression. (a) The expression of OXPHOS complex 
V (CV) was measured using immunocytochemistry after 4 hours dexamethasone treatment (10 µM, Dex). In 
addition, cells were incubated for 48 hours with rapamycin (500 nM) or resveratrol (10 µM) as known negative 
and positive regulators of mitochondrial mass. Mitochondria were stained with mitotracker red and nuclei 
with DAPI to determine the cellular localisation. (b) The mitochondrial CV expression was quantified using a 
mitochondrial mask based on the mitotracker red staining. Values were normalised to control (Ct): 40.4 ± 1.1 
arbitrary intensity units/mitochondrial pixel. Statistic analysis: one-way ANOVA with Dunnett’s post-hoc 
analysis: ***p < 0.001. Mean ± SEM, n ≥ 89 individual cells analysed in n = 3 independent experiments.
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Figure 7. Dexamethasone does not affect the OXPHOS complex IV expression. (a) The expression of OXPHOS 
complex IV (CIV) was measured using immunocytochemistry after 4 hours dexamethasone treatment (10 µM, 
Dex). In addition, cells were incubated for 48 hours with rapamycin (500 nM) or resveratrol (10 µM) as known 
negative and positive regulators of mitochondrial mass. Mitochondria were stained with mitotracker red and 
nuclei with DAPI to determine the cellular localisation. (b) The mitochondrial CIV expression was quantified 
using a mitochondrial mask based on the mitotracker red staining. Values were normalised to control (Ct): 
33.2 ± 1.5 arbitrary intensity units/mitochondrial pixel. Statistic analysis: one-way ANOVA with Dunnett’s post-
hoc analysis: ***p < 0.001. Mean ± SEM, n ≥ 89 individual cells analysed in n = 3 independent experiments.
www.nature.com/scientificreports/
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High-resolution respirometry. Cellular and mitochondrial respiration was measured at 37 °C using a 
two-chamber Oxygraph-2k equipped with Datlab 5 recording and analysis software (Oroboros Instruments), as 
described previously43–45. To determine the P:O ratio we slightly modified the previously described approach45, 46. 
For cellular respiration measurements, 1.5·106 cells were resuspended in mitochondrial respiration medium 
MiR05 (Oroboros Instruments) and transferred to the chambers of an Oxygraph-2k. After digitonin per-
meabilisation (10 µg/1·106 cells) of the cell membrane, malate (2 mM) and glutamate (10 mM) were added to 
determine the STATE 4 respiration. STATE 3 respiration was obtained by the addition of ADP (220 nM), after 
which the oxygen consumption rate could decrease to the level of STATE 4 respiration, indicating a complete 
conversion of ADP in ATP. The P:O ratio was calculated dividing the amount of ADP used by the amount of 
oxygen used by the mitochondria to use all the ADP. Next, the mitochondrial complex-specific respiration 
was determined using complex-specific substrates and ADP (4 mM). Glutamate (10 mM) and malate (2 mM) 
were used as CI substrates, succinate (10 mM) for CII and ascorbate (2 mM) plus TMPD (0.5 mM) as CIV sub-
strates. The glycerol-3-phosphate dyhydrogenase (G3PDH)-driven respiration was measured in the presence of 
glycerol-3-phosphate (20 mM) and flavine adenine dinucleotide (10 µM) and was terminated by antimycin A 
(2.5 µM). To inhibit CI and CII, rotenone (0.5 µM) and atpenin A5 (50 nM, Enzo Life Sciences) were added, 
respectively. Finally, the integrity of the mitochondrial outer membrane was tested using 10 µM cytochrome c 
(respiratory rate increase should be less than 10%)47.
Mitochondrial membrane potential analysis. Cells were seeded in 35 mm Fluorodishes (World 
Precision Instruments GmbH) and after exposure loaded with loaded with tetramethylrhodamine methyl ester 
(100nM) (TMRM, Thermo Fisher Scientific) for 25 minutes at 37 °C, 5% (v/v) CO2. Next, cells were washed twice 
using Krebs-Henseleit buffer supplemented with HEPES (10 mM, KHH) (pH 7.4), and images were captured 
using a temperature-controlled chamber connected to an inverted microscope (Axiovert 200M, Carl Zeiss) using 
a x63, 1.25 NA Plan NeoFluor oil immersion objective. As a positive control, the known uncoupling agent car-
bonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) was used at the end of each measurement. Images 
were corrected for background and uneven illumination followed by analysis where images were masked with a 
binarised image for mitochondrial morphology using Image Pro Plus software (version 6.3, Media Cybernetics) 
as previously described48.
Reactive oxygen species generation analysis. To measure cellular ROS, ciPTEC-T1 were seeded in 
flat bottom 96-well black/clear plates (Corning). ciPTEC-T1 cells were loaded with 5-(and-6)-chloromethyl-2′,7
′-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA, 10 µM, Thermo Fisher Scientific) in KHH 
buffer for 20 minutes at 37 °C, 5% (v/v) CO2. Mitochondrial ROS production was detected using hydroethidium 
(10 µM, Thermo Fisher Scientific). Subsequently, cells were washed twice using KHH buffer and imaging was 
performed using a BD Pathway 855 high-throughput microscope (Becton Dickinson) for endpoint CM-DCF 
intensity measurements. Images were background corrected and average CM-DCF or hydroethidium intensity 
per cellular pixel was determined Image Pro Plus software (version 6.3, Media Cybernetics). CM-DCF oxidation 
Figure 8. LPS-induced endotoxaemia alkalisation of the intracellular pH is reversed by dexamethasone co-
treatment. (a) Intracellular pH was measured after LPS and/or dexamethasone exposure (Dex) (Fig. 1a) using 
the ratiometric probe 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxy methyl ester (BCECF). 
pH levels were determined using ratio images, which were obtained by dividing the 490 nm by the 440 nm 
image, (b) and quantified on a single cell level. Statistic analysis: one-way ANOVA with Tukey’s post-hoc 
analysis to compare to vehicle control (Ct): *p < 0.05, **p < 0.01, ***p < 0.001. Mean ± SEM, n ≥ 77 individual 
cells analysed in n = 3 independent experiments.
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rates were determined using a Perkin Elmer Victor X3 fluorescent plate reader. CM-DCF intensity was read for 17 
minutes and subsequently corrected for the basal intensity of each well. Next, the oxidation rate was determined 
using the slope of the linear part of the plotted CM-DCF intensity.
OXPHOS complex and citrate synthase activities. Approximately 6·106 exposed ciPTEC-T1 cells were 
harvested and resuspended in Tris-HCl buffer (10 mM). Next, samples were pottered in the presence of sucrose 
(215 mM) to obtain a homogenous fraction. Samples were centrifuged for 10 minutes at 600 g to remove cellu-
lar debris. The supernatant containing mitochondria was centrifuged for 10 minutes at 14,000 g. The pellet was 
resuspended in Tris-HCl buffer (pH 7.6), snap frozen in liquid N2 and stored at -80 °C until usage. The catalytic 
capacity of the OXPHOS complexes was measured using a spectrophotometric method, as previously described49. 
Citrate synthase activity was determined simultaneously as described previously50. The catalytic activity of CI - IV 
and citrate synthase were corrected for mg cellular protein.
Cytosolic pH measurements. ciPTEC-T1 were seeded in 35 mm Fluorodishes (World Precision 
Instruments GmbH) and cultured accordingly. Cells were loaded with the cytosolic pH-sensitive reporter mole-
cule BCECF-AM (5 µM, 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxy methyl ester) (Thermo 
Fisher Scientific) in KHH buffer and incubated for 15 minutes at 37 °C. Cells were washed three times using 
KHH buffer and imaging was performed using an inverted microscope (Axiovert 200M, Carl Zeiss). BCECF flu-
orescence was sequentially excited at the isosbestic point (440 nm) (100 ms) and at the H+-sensitive wavelength 
(490 nm) (100 ms). Fluorescent images were captured at 530 nm emission wavelength. Images were analysed 
using Image Pro Plus software (version 6.3, Media Cybernetics). After background correction, the 490/440 emis-
sion ratio was used to quantify cellular pH45, 51.
Immunocytochemistry. We used µ-slide 8 well chambers (Ibidi GmbH) coated with human collagen IV 
(50 µg/ml in Hank’s Balanced Salt Solution (HBSS), Thermo Fisher Scientific) to allow the cells to attach. As 
controls, cells were exposed to resveratrol (10 µM) for 48 hours at 37 °C, 5% (v/v) CO2 to induce the expression of 
PCG-1α, COX (CIV) and CV, whereas rapamycin (500 nM) was used for 48 hours to attenuate the expression of 
the proteins of interest as it is a known mTOR-dependent mitophagy inducer. First, exposed ciPTEC were incu-
bated using mitotracker red (400nM, Thermo Fisher Scientific) for 30 minutes at 37 °C, 5% (v/v) CO2. Next, cells 
were fixed using 2% (w/v) paraformaldehyde in HBSS supplemented with 2% (w/v) sucrose for 5 minutes and 
permeabilised using 0.3% (v/v) Triton X-100 in HBSS for 10 minutes, all at room temperature (rT). To prevent 
a-specific binding of antibodies, cells were blocked using 2% FCS (v/v), 2% (w/v) BSA fraction V (Roche) and 
0.1% (v/v) Tween-20 in HBSS for 30 minutes. Next, cells were incubated against PCG-1α (1:50 dilution in block 
solution; clone 3G6; Cell Signaling Technology), COX (1:100 dilution in block solution; ab14705, Abcam) and CV 
(1:100 dilution in block solution; clone 7H10BD4F9, Mitosciences, Abcam) for 1 hour at rT. Subsequently, cells 
were incubated with goat-anti-rabbit- or goat-anti-mouse-Alexa488 conjugate (1:200, Abcam) and finally nuclei 
were stained using DAPI (300 nM, Thermo Fisher Scientific) for 5 minutes at rT. Images were captured using 
the Olympus FV1000 Confocal Laser Scanning Microscope (Olympus) and the Olympus software FV10-ASW 
version 1.7. Images were analysed using Image Pro Plus software (version 6.3, Media Cybernetics). For both COX 
and CV images, background was subtracted and subsequently a mitochondrial binary mask was created using 
the mitotracker red images. Next, the mitochondrial mask was combined with the COX or CV images and the 
intensity per mitochondrial pixel was quantified. The PGC-1α images were combined with a nuclear binary mask 
instead of a mitochondrial mask, which was made using the DAPI images.
Data analysis. All data are expressed as mean ± SEM of multiple independent replicates as indicated. 
Statistical analysis was performed using GraphPad Prism version 5.03. A one-way or two-way ANOVA analysis 
was performed followed by the appropriate post-hoc analysis as indicated.
Data availability. The datasets generated and/or analysed are available on reasonable request. All experi-
ments were performed in accordance with relevant guidelines and regulations.
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